Caribou Biosciences annual capital expenditures (capex)
2019
2020
2021
2022
2023
2024
2025
Caribou Biosciences Capital Expenditures (CapEx) Growth & History (CRBU)
Caribou Biosciences's capital expenditures (capex) was $1.4M for fiscal 2025.
View full Caribou Biosciences company overviewCaribou Biosciences annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.4M | −$3.5M | −72.15% |
| 2024 | 2024-12-31 | $4.9M | −$6.7M | −57.98% |
| 2023 | 2023-12-31 | $11.6M | $5.2M | +79.93% |
| 2022 | 2022-12-31 | $6.5M | $4.3M | +204.29% |
| 2021 | 2021-12-31 | $2.1M | $1.8M | +569.09% |
| 2020 | 2020-12-31 | $317,000 | −$567,000 | −64.14% |
| 2019 | 2019-12-31 | $884,000 | — | — |
Caribou Biosciences quarterly capital expenditures (capex)
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1,000 | −$417,000 | −99.76% |
| Q1 2026 | 2026-03-31 | $72,000 | −$970,000 | −93.09% |
| Q4 2025 | 2025-12-31 | $216,000 | −$302,000 | −58.30% |
| Q3 2025 | 2025-09-30 | $115,000 | −$558,000 | −82.91% |
| Q2 2025 | 2025-06-30 | $418,000 | −$1.8M | −81.35% |
| Q1 2025 | 2025-03-31 | $1.0M | −$406,000 | −28.04% |
| Q4 2024 | 2024-12-31 | $518,000 | −$1.8M | −77.25% |
| Q3 2024 | 2024-09-30 | $673,000 | −$4.1M | −85.84% |
| Q2 2024 | 2024-06-30 | $2.2M | −$312,000 | −12.22% |
| Q1 2024 | 2024-03-31 | $1.4M | −$583,000 | −28.71% |
| Q4 2023 | 2023-12-31 | $2.3M | $520,000 | +29.60% |
| Q3 2023 | 2023-09-30 | $4.8M | $3.4M | +250.96% |
| Q2 2023 | 2023-06-30 | $2.6M | −$67,000 | −2.56% |
| Q1 2023 | 2023-03-31 | $2.0M | $1.3M | +180.91% |
| Q4 2022 | 2022-12-31 | $1.8M | $1.1M | +156.50% |
| Q3 2022 | 2022-09-30 | $1.4M | $424,000 | +45.59% |
| Q2 2022 | 2022-06-30 | $2.6M | $2.1M | +441.32% |
| Q1 2022 | 2022-03-31 | $723,000 | $701,000 | +3186.36% |
| Q4 2021 | 2021-12-31 | $685,000 | — | — |
| Q3 2021 | 2021-09-30 | $930,000 | $916,000 | +6542.86% |
| Q2 2021 | 2021-06-30 | $484,000 | — | — |
| Q1 2021 | 2021-03-31 | $22,000 | — | — |
| Q3 2020 | 2020-09-30 | $14,000 | — | — |
Caribou Biosciences capital expenditures (capex) trends
Over the last five fiscal years, Caribou Biosciences's capital expenditures (capex) increased from $317,000 to $1.4M, a change of $1.0M. The latest reported quarter, Q2 2026, shows $1,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Caribou Biosciences source filings ↗